Daratumumab for Maintenance in Patients With Relapsed Multiple Myeloma After Salvage Autologous Stem Cell Transplantation
Phase of Trial: Phase II
Latest Information Update: 13 May 2019
Price : $35 *
At a glance
- Drugs Daratumumab (Primary)
- Indications Multiple myeloma
- Focus Therapeutic Use
- 12 Apr 2019 Status changed from not yet recruiting to recruiting.
- 30 Oct 2018 Planned initiation date changed from 30 Sep 2018 to 1 Jan 2019.
- 20 Aug 2018 New trial record